Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

NVAMD Satellite Study

28. august 2018 opdateret af: Johns Hopkins University

A Multi-Satellite Comparison of Standard-of-Care, Physician-Based Retinal Evaluation Versus Physician-Guided Diagnostic Evaluation in the Management of Neovascular Age-Related Macular Degeneration With Anti-Vascular Endothelial Growth Factor Therapy

Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD). However, the requirement for near monthly administration of therapy coupled with the growing number of patients needing treatment has become a universal challenge in efficient delivery of care for retina physicians. While many retina practices have both increased the size of their staffs to accommodate the growing patient population and increased efficiency with the aid of digital photography, patient encounter times in clinic continue to increase, often spanning 2-4 hours. While maintaining the highest level of patient care, a streamlined alternative in the evaluation of patients with NVAMD to determine whether intravitreal therapy with an anti-VEGF agent is indicated at a particular office visit would be desirable.

This multi-satellite, prospective, randomized pilot study will compare standard-of-care, physician- based retinal evaluation, defined as retinal examination by a physician and standard imaging with optical coherence tomography (OCT) and optional fluorescein angiography (FA), versus physician-guided diagnostic evaluation, defined as standard imaging with OCT and optional FA without retinal examination by a physician in the management of NVAMD with anti-VEGF therapy. Outcomes for this study are aimed primarily at demonstrating that the physician-guided diagnostic approach to managing patients with NVAMD is not inferior to the physician-based retinal evaluation based on measures such as a change from baseline in visual acuity and in central subfield thickness (CSF) on OCT. Other outcomes to be assessed in this study are length of visit times, numbers of intravitreal injections of anti-VEGF agents administered, numbers of diagnostic tests performed to determine whether treatment should be given at each visit, and frequency of retinal examinations performed for each participating patient in each cohort. Perceptions of quality of vision and patient satisfaction will be captured by interviews with patients following each clinic visit; clinical impressions of physicians will be captured by a brief physician survey. Finally, the feasibility of recruiting patients, as measured by how many eligible patients are seen at each Wilmer satellite, how many patients agree to be randomized, how many patients follow-up, and the attrition rates at the 4 and 8-month outcome visits will be assessed.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

66

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Maryland
      • Bel Air, Maryland, Forenede Stater, 21014
        • Wilmer Eye Institute
      • Bethesda, Maryland, Forenede Stater, 20814
        • Wilmer Eye Institute
      • Columbia, Maryland, Forenede Stater, 21044
        • Wilmer Eye Institute
      • Frederick, Maryland, Forenede Stater, 21702
        • Wilmer Eye Institute
      • Lutherville, Maryland, Forenede Stater, 21093
        • Wilmer Eye Institute

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria:

  • Established diagnosis of NVAMD in one or both eyes
  • Received 2 or more intravitreal injections of anti-VEGF therapy from the retinal physician during the prior 6 months
  • Need for more therapy on a near monthly basis is anticipated
  • Usual corrected visual acuity (UCVA) of at least one eye must be 20/200 or better
  • Must be physically able to cooperate with OCT and other diagnostic imaging procedures
  • Must be able to give informed consent and be able to complete telephone surveys

Exclusion criteria:

  • Systemic disease that can affect the peripheral retina (e.g., diabetes mellitus, sickle cell)
  • History of symptomatic posterior vitreous detachment, retinal tear, or retinal detachment
  • History of retinal surgery will not be enrolled.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: SOC Examination Based Cohort
Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
Aktiv komparator: Physician-Guided Diagnostic
Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Change in visual acuity from baseline
Tidsramme: up to two years
up to two years
Change in OCT CSF from baseline
Tidsramme: up to two years
up to two years

Sekundære resultatmål

Resultatmål
Tidsramme
total encounter time for each arm
Tidsramme: up to two years
up to two years

Andre resultatmål

Resultatmål
Tidsramme
Number of intravitreal anti-VEGF injections administered
Tidsramme: up to two years
up to two years
number of diagnostic tests performed
Tidsramme: up to two years
up to two years
number of retinal examinations performed
Tidsramme: up to two years
up to two years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Sharon Solomon, MD, Johns Hopkins University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. oktober 2014

Primær færdiggørelse (Faktiske)

30. oktober 2016

Studieafslutning (Faktiske)

30. oktober 2016

Datoer for studieregistrering

Først indsendt

9. september 2014

Først indsendt, der opfyldte QC-kriterier

25. september 2014

Først opslået (Skøn)

29. september 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

31. august 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. august 2018

Sidst verificeret

1. august 2018

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NA_00088759

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Physician-guided diagnostic

Abonner